Glaucoma

Rocklatan achieves non-inferiority to Ganfort and outperforms prior Phase 3 trials

A world-first clinical trial led by the Centre for Eye Research Australia shows vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma patients.

Assistant Editor Brooke Beery shares news updates for October 25, 2020.

Optometry news update

Eye physicals should be full-scope

Know options for treatment are available

New devices will monitor health, enhance vision, and treat the eye

Cross-sectional structures of the bulbar conjunctival tissue can be accurately measured

Apply lessons learned in glaucoma to treating macular degeneration

Study shows improved OBF throughout the retina with antioxidant supplementation

Frequency doubling technology may become the new holy grail of glaucoma imaging.

A comment from a patient prompts a doctor’s change in testing and discussion.

The different concerns in pediatric glaucoma compared with adults.

Case exhibits challenge of “atypical” disease presentation and potential for unneeded surgery.

Results from the EAGLE and ZAP clinical trials provide answers to lingering questions.

Reach past conventional therapies and give alternatives a try

During the Glaucoma 360 annual meeting, Dake K. Heuer, MD, delivered the Shaffer-Hetherington-Hoskins Lecture Keynote address, titled “Risk Factors for Glaucoma Progression.”

More knowledge helps dispel myths in diagnosing and treating this sight-stealing disease.

Modern optometry can provide advanced outcome support to patients with glaucoma.